Theis Terwey

Founder and Managing Director, n.cour projects GmbH

Berlin-based physician, biotech entrepreneur, and angel investor with over 20 years of experience across academic medicine, drug development, biopharma investment, and company building. Co-founder and former CEO of GH Research (NASDAQ: GHRS), guiding the company’s growth from inception through IPO and into Phase 2b clinical development, with over $300M raised across multiple rounds. Previously, partner at NB Capital ApS, focused on public and private investments across all stages of pharmaceutical development, and senior advisor at Forward Pharma A/S contributing to its $235M IPO and IP strategy that resulted in a $1.25B license agreement with Biogen. Currently angel investor with Springboard Health Angels and Business Angels Club Berlin-Brandenburg and advisor with SPARK-BIH. Holds a Doctor medicinae, specialist certification in internal medicine, and a Habilitation from Charité – University Medicine Berlin.